MONTREAL, April 4, 2018 – Glycovax Pharma Inc. (“Glycovax” or “the Company”), a leader in the development of new therapeutic strategies against cancer and infectious diseases, announced today that it has filed a patent application with the United States Patent and Trademark Office, entitled “Precision Glycoconjugate Vaccines”, as a novel semi-synthetic vaccine for the prevention and treatment of breast cancers.
Dr Serge Mignani, formerly Scientific Director of Sanofi, now Vice-President of Scientific Development at Glycovax commented on the significance of this patent application for the new semi-synthetic process: “This patent is of great importance because it is the design and development of semi-synthetic vaccines for the prevention and treatment of cancers, in this specific case breast cancers. The semi-synthetic aspect is due to the fact that the breast cancer antigens chosen for the vaccine preparation are synthesized by simple glycochemistry in the laboratory rather than being isolated from tumor cells”.
Glycovax is changing the thinking in pharmaceutical research by developing new complementary platforms, such as original therapeutic cancer vaccines, nanomedicine, imaging and diagnosis.
This revolutionary approach led, in the past, to the creation and commercialization of the first semi-synthetic conjugate vaccine Quimi-Hib®, which is still extremely efficient for preventing the onset of meningitis caused by the Haemophilus Influenzae type b bacteria. The Company is optimistic that this specific therapeutic cancer vaccine approach will also be a successful new strategy for the prevention and treatment of breast and other forms of cancers.
About Glycovax Pharma Inc.
Glycovax Pharma has designed a nanomedicine platform based on a completely new class of synthetic nanoparticles. To these new molecular entities can be added a wide range of active agents with multiple functions to treat cancers and other unmet medical needs. These novel nanoparticles can be used to target and deliver drugs directly to tumor cells but also to design preventive solutions. The Company has developed an efficient technology to develop semi-synthetic vaccines able to prevent and treat breast cancers and several other infectious pathologies. Glycovax goal is to reduce side effects of therapeutic agents and to meet the new challenges of the pharmaceutical industry by facilitating the production of high quality innovative drugs.
For information: www.glycovax.com
For media information, please contact:
Daniel Granger
Daniel.granger@acjcommunication.com,
ACJ Communication,
O: 1 514 840-7990 | M: 1 514 232-1556
Download PDF version HERE